The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
STARLITE 2: Phase 2 study of nivolumab plus 177Lutetium-labeled anti-carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab (177Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC).
 
Darren R. Feldman
Consulting or Advisory Role - Cigna
Research Funding - Astellas Pharma; Decibel Therapeutics (Inst); Seagen
Other Relationship - UpToDate
 
Robert J. Motzer
Consulting or Advisory Role - AstraZeneca; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Genentech/Roche; Incyte; Lilly; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Andrea Knezevic
Consulting or Advisory Role - ByHeart
 
Chung-Han Lee
Honoraria - American Institute of Continuing Medical Education; Intellisphere; Research to Practice
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Exelixis; Merck; Pfizer/EMD Serono
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst); Merck (Inst)
 
Martin H Voss
Stock and Other Ownership Interests - CellGenix (I)
Consulting or Advisory Role - Affimed Therapeutics; AVEO; Calithera Biosciences; Eisai; Exelixis; Genentech; Merck; Oncorena; OnQuality Pharmaceuticals; Pfizer
Research Funding - Pfizer
Other Relationship - BMS
(OPTIONAL) Uncompensated Relationships - Aravive; BMS; Genentech/Roche
 
Serge K. Lyashchenko
Leadership - Evergreen Theragnostics
Stock and Other Ownership Interests - Evergreen Theragnostics
Honoraria - GE Healthcare
Consulting or Advisory Role - Curie Therapeutics; YmAbs Therapeutics Inc
Travel, Accommodations, Expenses - Evergreen Theragnostics; YmAbs Therapeutics Inc
 
Hijin Park
Stock and Other Ownership Interests - Evergreen Theragnostics; YmAbs Therapeutics Inc
 
Steven M. Larson
Stock and Other Ownership Interests - Elucida Oncology; YmAbs Therapeutics Inc
Research Funding - YmAbs Therapeutics Inc
Patents, Royalties, Other Intellectual Property - YmAbs Therapeutics Inc
 
Neeta Pandit-Taskar
Honoraria - Actinium Pharmaceuticals
Consulting or Advisory Role - Actinium Pharmaceuticals; Fusion Pharmaceuticals; Illumina; progenics
Speakers' Bureau - Actinium Pharmaceuticals
Research Funding - Bayer Health (Inst); Bristol-Myers Squibb (Inst); Clarity Pharmaceuticals (Inst); Fusion Pharmaceuticals (Inst); Imaginab (Inst); Janssen (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Bayer